Effects of Hepatic Impairment on the Pharmacokinetics of Abrocitinib and Its Metabolites

Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

(2020) Eric L Simpson et al.   LANCET

Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis

(2020) Jonathan I. Silverberg et al.   JAMA Dermatology

Management Recommendations for Dupilumab Partial and Non-durable Responders in Atopic Dermatitis

(2019) Aleksi J. Hendricks et al.   AMERICAN JOURNAL OF CLINICAL DERMATOLOGY

Pain Is a Common and Burdensome Symptom of Atopic Dermatitis in United States Adults

(2019) Jonathan I. Silverberg et al.   Journal of Allergy and Clinical Immunology-In Practice

Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis

(2019) Melinda J. Gooderham et al.   JAMA Dermatology

New treatments for atopic dermatitis targeting beyond IL-4/IL-13 cytokines

(2019) Yael Renert-Yuval et al.   ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY

Atopic dermatitis yardstick: Practical recommendations for an evolving therapeutic landscape

(2018) Mark Boguniewicz et al.   ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY

Evaluation of a Janus kinase 1 inhibitor, PF-04965842, in healthy subjects: A phase 1, randomized, placebo-controlled, dose-escalation study

(2018) Elena Peeva et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Efficacy and safety of the Janus kinase 1 inhibitor PF-04965842 in patients with moderate-to-severe psoriasis: phase II, randomized, double-blind, placebo-controlled study

(2018) G.J. Schmieder et al.   BRITISH JOURNAL OF DERMATOLOGY

Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases

(2018) Michael L. Vazquez et al.   JOURNAL OF MEDICINAL CHEMISTRY

Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II

(2018) A. Wollenberg et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Therapeutic pipeline for atopic dermatitis: End of the drought?

(2017) Amy S. Paller et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Impact of Genetic Polymorphisms in CYP2C9 and CYP2C19 on the Pharmacokinetics of Clinically Used Drugs

(2012) Takeshi Hirota et al.   Drug Metabolism and Pharmacokinetics

Nonlesional atopic dermatitis skin is characterized by broad terminal differentiation defects and variable immune abnormalities

(2011) Mayte Suárez-Fariñas et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Which Human Metabolites Have We MIST? Retrospective Analysis, Practical Aspects, and Perspectives For Metabolite Identification and Quantification in Pharmaceutical Development

(2009) Laurent Leclercq et al.   CHEMICAL RESEARCH IN TOXICOLOGY